NZ762060B2 - Use of 3-methylmethcathinone - Google Patents
Use of 3-methylmethcathinone Download PDFInfo
- Publication number
- NZ762060B2 NZ762060B2 NZ762060A NZ76206018A NZ762060B2 NZ 762060 B2 NZ762060 B2 NZ 762060B2 NZ 762060 A NZ762060 A NZ 762060A NZ 76206018 A NZ76206018 A NZ 76206018A NZ 762060 B2 NZ762060 B2 NZ 762060B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- approximately
- subject
- mmc
- distress
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Abstract
The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In particular, methods and kits for drug-assisted psychotherapy with 3-MMC for a variety of disorders and/or conditions, including PTSD, GAD and relationship distress are provided.
Claims (19)
1. Use of 3-methylmethcathinone (3-MMC) in the manufacture of a medicament for treating a subject undergoing a psychotherapeutic intervention.
2. The use of claim 1, wherein said 3-MMC is to be administered prior to said therapeutic intervention.
3. The use of claim 1, wherein said 3-MMC is to be administered during said psychotherapeutic intervention.
4. The use of claim 3, wherein said 3-MMC is to be administered at least twice during said psychotherapeutic intervention.
5. The use of claim 1, wherein said 3-MMC is to be administered after said psychotherapeutic intervention.
6. The use of any one of claims 1-5, wherein said 3-MMC is to be administered to said subject in an amount of approximately 50 mg to approximately 500 mg per therapeutic intervention.
7. The use of claim 6, n said 3-MMC is to be administered to said subject in an amount of approximately 100 mg to approximately 400 mg per therapeutic intervention.
8. The use of claim 6, wherein said 3-MMC is to be stered to said subject in an amount of imately 100 mg to approximately 200 mg per therapeutic intervention.
9. The use of any one of claims 1-8, wherein said 3-MMC is to be administered to said subject in an amount of approximately 25 mg, approximately 50 g, approximately 75 mg, approximately 100 mg, approximately 125 mg, approximately 150 mg, approximately 175 mg or approximately 200 mg per therapeutic intervention.
10. The use of any one of claims 1-9, wherein said psychotherapeutic intervention is for distress of said subject.
11. The use of claim 10, wherein said treating is for ng said distress in said subject.
12. The use of claim 10 or 11, wherein said distress is selected from the group consisting of cognitive, nal, behavioral, relationship and spiritual distress.
13. The use of any one of claims 10-12, wherein said distress is a condition or er selected from the group consisting of personal history of psychological trauma, parentchild relational problem, personal history (past history) of neglect in childhood, personal history (past history) of physical abuse in childhood, personal history (past y) of psychological abuse in childhood, personal history (past history) of sexual abuse in childhood, personal history (past history) of spouse or partner neglect, personal history (past history) of spouse or partner psychological abuse, personal history (past history) of spouse or partner physical violence, personal history (past history) of spouse or partner sexual violence, phase of life problem, relationship distress with spouse or intimate partner, stimulant use disorder and aumatic stress disorder.
14. The use of any one of claims 10-12, n said subject is diagnosed with a stress-sensitive disorder ed from the group consisting of Post-traumatic Stress er (PTSD), Bipolar Disorder, Acute Stress Disorder, anxiety disorders such as lized y Disorder, Obsessive-Compulsive Disorder, social anxiety ers, Panic Disorders, s, obsessive compulsive disorders, and Trichotillomania.
15. The use of any one of claims 1-14, wherein said therapeutic intervention is selected from the group consisting of psychoanalytic and psychodynamic therapy, behavioral therapy, ive therapy, humanistic therapy and integrative or holistic therapy.
16. The use of claim 15, wherein said psychotherapeutic intervention is humanistic therapy or integrative/holistic therapy.
17. The use of claim 10, wherein reducing said distress comprises at least one of the following: improving stability in the work/home environment, improving behaviors, improving employment functioning, improving vocational functioning, ng cognitive stress, reducing emotional stress, improving the subject’s living situation, improving the subject’s family relationships, improving social relationships, ing the subject’s sense of meaning to life, improving the subject’s sense of purpose to life, reducing mental health symptoms, reducing ion behaviors and reducing chemical dependencies.
18. The use of claim 10, wherein reducing said distress comprises reducing the number and/or frequency of psychotherapeutic interventions, and/or reducing addiction ors and reducing chemical dependencies.
19. The use of claim 1, substantially as herein described with reference to any one of the Examples thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540617P | 2017-08-03 | 2017-08-03 | |
| PCT/IB2018/055812 WO2019026019A1 (en) | 2017-08-03 | 2018-08-02 | Use of 3-methylmethcathinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ762060A NZ762060A (en) | 2024-07-26 |
| NZ762060B2 true NZ762060B2 (en) | 2024-10-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liao et al. | [Retracted] Correlation between sleep time, sleep quality, and emotional and cognitive function in the elderly | |
| Seppi et al. | Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review | |
| Czeisler et al. | Modafinil for excessive sleepiness associated with shift-work sleep disorder | |
| Greer et al. | Improvements in psychosocial functioning and health‐related quality of life following exercise augmentation in patients with treatment response but nonremitted major depressive disorder: Results from the tread study | |
| Perlis et al. | Behavioral treatment of insomnia: treatment outcome and the relevance of medical and psychiatric morbidity | |
| Pease et al. | Insights into epileptogenesis from post-traumatic epilepsy | |
| Warner et al. | Identifying and managing posttraumatic stress disorder | |
| JP2020530032A5 (en) | ||
| FI3661491T3 (en) | 3-methylmethcathinone for use in treating a subject undergoing a psychotherapeutic intervention | |
| Iacono et al. | Chronic traumatic encephalopathy: known causes, unknown effects | |
| Mokhber et al. | Therapeutic effect of A vonex, R ebif and B etaferon on quality of life in multiple sclerosis | |
| French et al. | Influence of bodily injuries on symptom reporting following uncomplicated mild traumatic brain injury in US military service members | |
| NZ762060B2 (en) | Use of 3-methylmethcathinone | |
| Michael Hertzberg | The perioperative implications of posttraumatic stress disorder | |
| Heim et al. | International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the non-motor symptoms of Parkinson’s disease | |
| Bruce et al. | Sleep and cognition in older adults | |
| Gierat-Haponiuk et al. | Exercise capacity and the quality of life late after surgical correction of congenital heart defects | |
| Wei et al. | Pilot scheme of health policy in stroke adjuvant acupuncture therapy for acute and subacute ischemic stroke in Taiwan | |
| Mandell | Decisions about treating community-acquired pneumonia | |
| Masaud et al. | Holistic psycho-spiritual approach to enhance the effectiveness of Methadone Maintenance Therapy (MMT) | |
| Pysz-Waberski et al. | Treatment of chronic pain in oncology: cooperation between the oncologist and psychooncologist | |
| Narodova et al. | Efficiency and safety of the author's method of wrist tapping as a personalized method of emergency self-help in focal epilepsy | |
| Virani et al. | Violence associated with somatic delusions | |
| Ayoub et al. | 104. Modafinil Exerts Dose-Dependent Effects on Risk-Taking as Measured by the Human Iowa Gambling Task | |
| Kamamuta et al. | Involvement of fatigue in the effect of transcranial magnetic stimulation (TMS) on depression following COVID-19 and COVID-19 vaccination: a before-after study |